AVTX

Avalo Therapeutics Inc

Add to Watchlist

Advanced Chart

6.250

+0.59(10.424%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

6.500

Open

5.600

VWAP

6.16

Vol

801.17K

Mkt Cap

67.67M

Low

5.500

Amount

4.94M

EV/EBITDA(TTM)

Total Shares

1.03M

-57.37M

EV/OCF(TTM)

P/S(TTM)

Avalo Therapeutics, Inc. is a clinical-stage biotechnology company focused on the treatment of immune dysregulation. The Company's lead asset is AVTX-009, an anti-IL-1β mAb, targeting inflammatory diseases. AVTX-009 is a humanized monoclonal antibody (IgG4) that binds to interleukin-1β (IL-1β) with high affinity and neutralizes its activity. IL-1β is a central driver in the inflammatory process. Overproduction or dysregulation of IL-1β is implicated in many autoimmune and inflammatory diseases. IL-1β is a major, validated target for therapeutic intervention. There is evidence that inhibition of IL-1β could be effective in hidradenitis suppurativa and a variety of inflammatory diseases in dermatology, gastroenterology, and rheumatology. AVTX-009 is in the Phase II LOTUS trial for hidradenitis suppurativa (HS).

2 Analyst Rating

340.00% Upside

Wall Street analysts forecast AVTX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for AVTX is 27.50 USD with a low forecast of 15.00 USD and a high forecast of 40.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

2 Buy

0 Hold

0 Sell

Moderate Buy

340.00% Upside

Current: 6.250

Low

15.00

Averages

27.50

High

40.00

340.00% Upside

Current: 6.250

Low

15.00

Averages

27.50

High

40.00

H.C. Wainwright

Mitchell Kapoor

initiated

$15

2025-06-02

Reason

H.C. Wainwright

Mitchell Kapoor

Price Target

$15

2025-06-02

initiated

Reason

H.C. Wainwright analyst Mitchell Kapoor assumed coverage of Avalo Therapeutics with a Buy rating and $15 price target. Avalo is a clinical-stage biotech company developing therapeutics for immunological diseases, the analyst tells investors in a research note. The firm says AVTX-009 is initially being developed to treat hidradenitis suppurativa, which is a large indication with an evolving standard-of-care regimen.

Jefferies

Kambiz Yazdi

Strong Buy

Initiates

$23

2025-03-25

Reason

Jefferies

Kambiz Yazdi

Price Target

$23

2025-03-25

Initiates

Strong Buy

Reason

Jefferies analyst Kambiz Yazdi initiated coverage of Avalo Therapeutics with a Buy rating and $23 price target. Avalo is a clinical stage biotechnology company focused on immunology and inflammation led by a veteran management team, the analyst tells investors in a research note. The firm says Avalo's lead asset AVTX-009 is an IL-1beta antibody in Phase 2 for the treatment of moderate to severe hidradenitis suppurativa with topline data expected in 2026. It thinks AVTX-009 is de-risked in part by lutikizumab data and that Avalo has an angle to show a differentiated profile.

Stifel

Alex Thompson

Strong Buy

Initiates

$36

2025-03-25

Reason

Stifel

Alex Thompson

Price Target

$36

2025-03-25

Initiates

Strong Buy

Reason

HC Wainwright & Co.

Edward White

Hold

Reiterates

n/a

2025-03-20

Reason

HC Wainwright & Co.

Edward White

Price Target

n/a

2025-03-20

Reiterates

Hold

Reason

Piper Sandler

Yasmeen Rahimi

Buy

Initiates

$48

2025-02-28

Reason

Piper Sandler

Yasmeen Rahimi

Price Target

$48

2025-02-28

Initiates

Buy

Reason

BTIG

Julian Harrison

Strong Buy

Initiates

$40

2024-12-19

Reason

BTIG

Julian Harrison

Price Target

$40

2024-12-19

Initiates

Strong Buy

Reason

BTIG analyst Julian Harrison initiated coverage of Avalo Therapeutics with a Buy rating and $40 price target. The firm sees the company's AVTX-009 as having best-in-class features that could support preferred positioning in several large indications. Avalo's lead efforts are in hidradenitis suppurativa, where BTIG continues to expect significant reward for more active treatment options, even after key IL-17A/F inhibitors are expected to be well-established, the analyst tells investors in a research note.

See All Ratings

Valuation Metrics

The current forward P/E ratio for Avalo Therapeutics Inc (AVTX.O) is -1.02, compared to its 5-year average forward P/E of -2.51. For a more detailed relative valuation and DCF analysis to assess Avalo Therapeutics Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-2.51

Current PE

-1.02

Overvalued PE

-0.42

Undervalued PE

-4.60

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

0.00

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

0.00

Undervalued EV/EBITDA

0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

193.09

Current PS

0.00

Overvalued PS

1556.84

Undervalued PS

-1170.66